<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Dextromethorphan misuse and poisoning: Clinical features and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Dextromethorphan misuse and poisoning: Clinical features and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Dextromethorphan misuse and poisoning: Clinical features and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Chris Rosenbaum, MD, MSc, FACEP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Edward W Boyer, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michele M Burns, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Evan Schwarz, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The epidemiology, pertinent pharmacology, and clinical features of
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         poisoning will be reviewed here. The treatment of dextromethorphan poisoning is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6492.html" rel="external">
          "Dextromethorphan poisoning: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately one million United States youth and young adults (age 12 to 25 years) misuse over-the-counter (OTC) cough and cold medicines that contain
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         (DXM) each year [
         <a href="#rid1">
          1
         </a>
         ]. Nonmedical use of DXM results in approximately 6000 emergency department (ED) visits annually in the United States [
         <a href="#rid2">
          2
         </a>
         ]. Adolescents (age 12 to 20 years) account for almost 50 percent of ED visits. Co-ingestion of ethanol is frequently seen. Reports from other countries suggest that DXM misuse is prevalent outside of the United States as well [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         Initially introduced in tablet form during the late 1950s as the OTC cough suppressant Romilar, DXM has a long history of misuse. Because of diversion to recreational use, Romilar was removed from the OTC market in 1973 [
         <a href="#rid5">
          5,6
         </a>
         ]. Subsequently, pharmaceutical companies introduced liquid formulations that were designed to reduce misuse by creating an unpleasant taste if ingested in large amounts [
         <a href="#rid6">
          6
         </a>
         ]. Before geltabs became more widely available, it took approximately one bottle of cough syrup to achieve a euphoric effect [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Recreational DXM misuse is known as "going pharming," "Dexing," "Robodosing," or "Robotripping" among adolescent and adult users [
         <a href="#rid8">
          8-10
         </a>
         ]. Myriad slang terms exist for DXM based upon tablet appearance and their similarities with popular candies  (
         <a class="graphic graphic_table graphicRef66199" href="/z/d/graphic/66199.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         In 2006, Coricidin, Nyquil, and Robitussin formulations accounted for almost 66 percent of reported instances of DXM misuse among United States persons between the ages of 12 to 25 years [
         <a href="#rid1">
          1
         </a>
         ]. These cough medicines often combine DXM with
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , antihistamines, or decongestants [
         <a href="#rid7">
          7,8,11-15
         </a>
         ]. In order to extract DXM from unwanted products in combination cold preparations, individuals sometimes perform a two-phase acid base extraction technique using common household products ("Agent Lemon" technique) [
         <a href="#rid16">
          16
         </a>
         ]. This technique was applied quantitatively to 295 mL of a combination cough and flu medication and found to markedly reduce the amount of acetaminophen and
         <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">
          pseudoephedrine
         </a>
         in the final product while yielding significant quantities of DXM and
         <a class="drug drug_general" data-topicid="8796" href="/z/d/drug information/8796.html" rel="external">
          doxylamine
         </a>
         [
         <a href="#rid17">
          17
         </a>
         ]. Others prefer a single phase acid base extraction technique that results in a substance known as "Crystal Dex" [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         DXM may encourage initiation and progression of substance use in adolescents [
         <a href="#rid18">
          18
         </a>
         ]. Some younger adolescents consider DXM to be a harmless and legal high [
         <a href="#rid19">
          19
         </a>
         ]. Because it is easily available and produces an intense effect, DXM may entice young users to experience broader and illicit substance use experiences [
         <a href="#rid19">
          19
         </a>
         ]. For example, among young adults who ever misused DXM, 82, 49, and 44 percent reported use of cannabis, inhalants, or hallucinogens (eg, lysergic acid diethylamide [LSD], phencyclidine [PCP], 3,4-methylenedioxymethamphetamine [ecstasy, MDMA]), respectively [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PHARMACOLOGY AND CELLULAR TOXICOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          Dextromethorphan
         </a>
         (DXM) is the D- isomer of the
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         synthetic analog,
         <a class="drug drug_general" data-topicid="9556" href="/z/d/drug information/9556.html" rel="external">
          levorphanol
         </a>
         . DXM also contains an alkylated amine adjacent to a cyclohexane ring, a chemical structure that is seen in other dissociative agents (eg,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , phencyclidine [PCP]). (See
         <a class="medical medical_review" href="/z/d/html/298.html" rel="external">
          "Ketamine poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6506.html" rel="external">
          "Phencyclidine (PCP) intoxication in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         DXM is marketed as a nonsedating and non-habit-forming cough suppressant.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Formulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are over 140 products that contain DXM available worldwide, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Combination cough syrups (concentration range 5 to 40 mg per 5 mL, often combined with antihistamine,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         ,
         <a class="drug drug_general" data-topicid="8503" href="/z/d/drug information/8503.html" rel="external">
          guaifenesin
         </a>
         and/or
         <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">
          pseudoephedrine
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sustained release cough syrup suspensions (eg, Delsym, 30 mg per 5 mL)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liquid filled capsules (15, 30 mg)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral strips (7.5, 15 mg)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lozenges (5, 7.5, 10 mg)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Toxic dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         DXM toxicity occurs in a dose dependent fashion. Neurobehavioral effects typically begin 30 to 60 minutes post-ingestion and persist for up to six hours [
         <a href="#rid20">
          20
         </a>
         ]. The different stages of effect are often referred to as "plateaus" by users [
         <a href="#rid21">
          21,22
         </a>
         ], and are listed below along with the approximate range of doses associated with them:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild stimulation (first "plateau"): 1.5 mg/kg (adult dose: 100 to 200 mg)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Euphoria and hallucinations (second "plateau"): 2.5 to 7.5 mg/kg (adult dose: 200 to 400 mg)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dissociative "out of body" state (third "plateau"): 7.5 to 15 mg/kg (adult dose: 300 to 600 mg)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete dissociation with unresponsiveness (fourth "plateau"): 15 mg/kg (adult dose: &gt;600 mg)
        </p>
        <p>
        </p>
        <p>
         DXM may produce a life-threatening serotonin syndrome when co-ingested with monoamine oxidase inhibitors or other serotonergic agents (eg, serotonin specific reuptake inhibitors,
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         , cocaine)  (
         <a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">
          table 2
         </a>
         ), even in a regular daily dose. (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         .)
        </p>
        <p>
         DXM cough and cold products frequently contain
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , antihistamines, or
         <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">
          pseudoephedrine
         </a>
         that has significant toxic potential as well. (See
         <a class="local">
          'Co-ingestant findings'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/318.html" rel="external">
          "Acetaminophen (paracetamol) poisoning: Management in adults and children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         In regular daily dosing, DXM's antitussive effect derives from the binding of sigma opioid receptors in the medulla by the active metabolite, dextrorphan. Because of its stereochemistry, DXM and its metabolites do not bind the mu and delta opioid receptors, thus avoiding classic opioid toxicity [
         <a href="#rid23">
          23
         </a>
         ]. Dextrorphan also has serotonergic activity at the 5-hydroxytryptophan 2 receptor which explains why a regular dose of DXM can cause serotonin syndrome, especially when co-ingested with other serotonin agonists (eg, monoamine oxidase inhibitors) [
         <a href="#rid24">
          24-26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         .)
        </p>
        <p>
         In overdose, the active metabolite, dextrorphan, inhibits N-methyl-d-aspartate (NMDA) receptors. This action results in neurobehavioral effects similar to
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and phencyclidine (PCP) including hallucinations, "out of body" sensation, and dissociation. DXM also inhibits adrenergic neurotransmitter reuptake in the peripheral and central nervous system resulting in tachycardia, hypertension, and diaphoresis [
         <a href="#rid18">
          18,27-29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          KINETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pharmacokinetics of
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         (DXM) are as follows [
         <a href="#rid18">
          18,23,30-33
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         DXM is well absorbed with peak serum concentration occurring 2.5 hours after oral ingestion of a regular dose [
         <a href="#rid18">
          18
         </a>
         ]. Volume of distribution is estimated at 5 to 6.7 L/kg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         DXM undergoes metabolism in the liver via cytochrome CYP2D6 to dextrorphan (primary active metabolite) and 3-methoxymorphinan [
         <a href="#rid18">
          18,31,33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peak plasma concentration of the active metabolite, dextrorphan, is achieved at 1.6 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Average half-life of the parent compound in therapeutic use is approximately three hours in individuals who are rapid metabolizers and 30 hours in slow metabolizers [
         <a href="#rid34">
          34
         </a>
         ]. DXM and its metabolites, dextrorphan and 3-methoxymorphinan, are almost exclusively renally excreted [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The neurobehavioral effects of DXM are primarily mediated by the action of the metabolite, dextrorphan at the N-methyl-d-aspartate (NMDA) receptor. Individual response to DXM ingestion is strongly affected by the genetically determined activity of the CYP2D6 enzyme. Approximately 85 percent of the US population have high CYP2D6 activity and would be expected to rapidly develop high dextrorphan concentrations after overdose. Medications that inhibit cytochrome CYP2D6 (eg, monoamine oxidase inhibitors,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ) increase DXM concentrations, decrease dextrorphan concentrations, and thus dampen the associated neurobehavioral effects [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="local">
          'Mechanism of action'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         Historical features of
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         (DXM) poisoning vary significantly by age.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Youth and adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         DXM misuse is most frequent in adolescents and young adults [
         <a href="#rid1">
          1
         </a>
         ]. These patients often arrive in the emergency department (ED) with altered mental status and may not provide a history. Witnesses of the ingestion or emergency medical services (EMS) personnel, who may have recovered containers at the scene, should be interviewed in this setting. Key information includes the specific DXM containing substance, amount ingested, time of ingestion, and co-ingestion of ethanol, serotonergic agents (especially ecstasy [3,4-methylenedioxymethamphetamine]), or other recreational drugs.
        </p>
        <p>
         Additional history should identify the likelihood of trauma (particularly head trauma) and rape. Often, EMS reports regarding the environment in which the patient was found and whether the patient was partially or fully undressed can assist in identifying physical or sexual assault.
        </p>
        <p>
         Up to 14 percent of DXM overdoses in teenagers and young adults seen in the emergency department are part of a suicide attempt [
         <a href="#rid2">
          2
         </a>
         ]. Thus, direct questioning regarding suicidal intent should occur in all intentional DXM ingestions. If suicidal ideation is present, further mental health evaluation is indicated after the patient recovers from the intoxication.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants and young children intoxicated by DXM, may also present with an intercurrent viral illness and sudden change in behavior. Fever is variably present. The caretaker should be carefully questioned about the use of over-the-counter (OTC) medications including the exact name of the medication, the amount of medication being given, and the frequency of dosing. Although OTC cough and cold medications intended for use in children under two years of age have been removed from the United States market, caregivers may still have supplies at home or may give liquid formulations intended for older children.
        </p>
        <p>
         Exploratory ingestions of OTC cough and cold medications occur frequently in young children. As a general rule, ingestion of an amount that is less than the estimated total daily dose for the child does not produce significant toxicity other than self-limited lethargy [
         <a href="#rid35">
          35
         </a>
         ]. In this circumstance, caretakers should also be questioned regarding other medications in the house and asked to check the home for signs of other toxic exposures. The patient's or caretaker's pharmacy may provide valuable information regarding prescribed medications available for ingestion, the date of the most recent refill, and the total number of pills dispensed. (See
         <a class="medical medical_review" href="/z/d/html/16258.html" rel="external">
          "Over-the-counter cough and cold preparations: Approach to pediatric poisoning", section on 'Dextromethorphan'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Physical examination
         </span>
        </p>
        <p class="headingAnchor" id="H16200405">
         <span class="h3">
          Acute overdose
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following acute overdose DXM produces several characteristic physical findings that may be variably present depending on the dose ingested [
         <a href="#rid7">
          7,8,21,28,29,36
         </a>
         ] (see
         <a class="local">
          'Toxic dose'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurobehavioral changes that include euphoria, hallucinations, inappropriate laughing, psychosis with dissociative features, agitation, and coma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tachycardia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dilated pupils
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diaphoresis (in the absence of anticholinergic co-ingestion)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Zombie-like" ataxic gait
        </p>
        <p>
        </p>
        <p>
         Tachycardia is such a consistent finding that its absence should call in to question the diagnosis of DXM intoxication unless the patient is also taking another agent (eg, beta-blocker, calcium channel blocker,
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ) that would prevent tachycardia.
        </p>
        <p>
         Agitation in association with severe DXM intoxication may also result in hyperthermia and metabolic acidosis with potential for rhabdomyolysis [
         <a href="#rid7">
          7,8,21,28,29
         </a>
         ].
        </p>
        <p>
         DXM may precipitate serotonin toxicity/syndrome (altered mental status, seizures, autonomic instability, and/or muscular hypertonicity  (
         <a class="graphic graphic_algorithm graphicRef138424" href="/z/d/graphic/138424.html" rel="external">
          algorithm 1
         </a>
         )) in overdose and when combined with monoamine oxidase inhibitors, serotonin specific reuptake inhibitors,
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          tramadol
         </a>
         , and other serotonergic agents [
         <a href="#rid25">
          25,37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         .)
        </p>
        <p>
         Nystagmus is sometimes seen, but this finding may also indicate serotonin toxicity/syndrome, ethanol intoxication, anticonvulsant overdose,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         toxicity, or PCP exposure.
        </p>
        <p>
         Respiratory depression and apnea have occurred in infants and young children [
         <a href="#rid38">
          38,39
         </a>
         ]. Dystonia responsive to
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         has also been described [
         <a href="#rid29">
          29,36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16199575">
         <span class="h3">
          Co-ingestant findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to DXM, over-the-counter cough formulations frequently contain other pharmaceutical agents such as
         <a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">
          chlorpheniramine
         </a>
         or other antihistamines,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , or
         <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">
          pseudoephedrine
         </a>
         whose toxicity may complicate DXM poisoning [
         <a href="#rid40">
          40
         </a>
         ]  (
         <a class="graphic graphic_table graphicRef94240" href="/z/d/graphic/94240.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Co-ingestion of antihistamines with high H1-receptor antagonist properties (eg,
         <a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">
          chlorpheniramine
         </a>
         ) can cause features of anticholinergic (antimuscarinic) poisoning such as tachycardia, hypertension, hyperthermia, flushing, warm and dry skin, sluggishly reactive pupils, delirium, and agitation  (
         <a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">
          table 4
         </a>
         ). Rarely, seizures and rhabdomyolysis may occur [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alpha-1 adrenergic agonist decongestants (eg,
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         or
         <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">
          pseudoephedrine
         </a>
         ), typically causes tachycardia or reflex bradycardia with hypertension. Headache, agitation, and hypertensive emergency may develop in patients with severe toxicity. (See
         <a class="medical medical_review" href="/z/d/html/94636.html" rel="external">
          "Phenylephrine and related decongestants: Pediatric poisoning", section on 'Clinical features and diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          Acetaminophen
         </a>
         is commonly present in cough and cold preparations. Although it rarely causes immediate symptoms, acetaminophen has high potential to cause severe delayed hepatotoxicity, hepatic failure, and death. It is imperative for the emergency provider to obtain an acetaminophen concentration in all patients with serious DXM exposure in order to detect this threat. (See
         <a class="medical medical_review" href="/z/d/html/340.html" rel="external">
          "Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/318.html" rel="external">
          "Acetaminophen (paracetamol) poisoning: Management in adults and children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16200151">
         <span class="h3">
          Signs of chronic use
         </span>
         <span class="headingEndMark">
          —
         </span>
         A rapidly progressive tolerance is frequently described by experienced DXM users [
         <a href="#rid6">
          6,21,41,42
         </a>
         ]. Repeated DXM use has also been associated with toxic psychosis and cognitive deterioration [
         <a href="#rid41">
          41,43-45
         </a>
         ]. In addition, habitual use and craving may occur in susceptible individuals [
         <a href="#rid7">
          7,46
         </a>
         ]. Abrupt cessation of DXM in these patients may result in dysphoria and intense craving [
         <a href="#rid41">
          41-44
         </a>
         ].
        </p>
        <p>
         Because DXM is produced as the crystalline hydrobromide salt, bromism marked by fatigue, ataxia, headache, and memory loss is a rare consequence that has also been observed in heavy chronic users of DXM [
         <a href="#rid47">
          47
         </a>
         ]. A negative anion gap or elevated chloride concentration on serum laboratory testing should raise the concern for bromism [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24717497">
         <span class="h1">
          ANCILLARY STUDIES
         </span>
        </p>
        <p class="headingAnchor" id="H24717633">
         <span class="h2">
          Acetaminophen concentration
         </span>
         <span class="headingEndMark">
          —
         </span>
         A serum
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         concentration should be obtained in all patients with
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         (DXM) exposure, including asymptomatic patients, unless co-ingestion of acetaminophen can be reliably excluded. Serum acetaminophen should also be obtained in patients who ingested DXM with suicidal intent.
        </p>
        <p>
         The serum
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         concentration should be measured between 4 and 24 hours after a single acute overdose of an immediate-release preparation and plotted on the modified Rumack-Matthew nomogram  (
         <a class="graphic graphic_figure graphicRef83590" href="/z/d/graphic/83590.html" rel="external">
          figure 1
         </a>
         ) to determine the need for antidotal therapy with
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          N-acetylcysteine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/340.html" rel="external">
          "Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation", section on 'General approach and laboratory evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17161.html" rel="external">
          "Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents", section on 'Acetaminophen concentration'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24717639">
         <span class="h2">
          Other studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Further laboratory evaluation of DXM intoxication varies depending on the clinical findings. Other ancillary studies may be indicated in selected patients in whom ingestion of other toxic agents, trauma, or sexual assault are suspected. (See
         <a class="medical medical_review" href="/z/d/html/6225.html" rel="external">
          "Evaluation of stupor and coma in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">
          "Approach to the child with occult toxic exposure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6571.html" rel="external">
          "Trauma management: Approach to the unstable child"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2765.html" rel="external">
          "Evaluation and management of adult and adolescent sexual assault victims in the emergency department"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13846.html" rel="external">
          "Testing for drugs of abuse (DOAs)", section on 'Drug-facilitated sexual assault'
         </a>
         .)
        </p>
        <p>
         We suggest the following tests in patients with altered mental function and suspected DXM overdose:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bedside glucose determination, to exclude hypoglycemia as the cause of altered consciousness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arterial or venous blood gas measurement and continuous pulse oximetry to evaluate the adequacy of ventilation in patients with serious and persistent central nervous system depression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum electrolyte determination to assess for electrolyte disturbance and to calculate the anion gap in the setting of likely co-ingestants or evidence for metabolic acidosis. A negative anion gap or elevated chloride concentration should prompt a consideration for possible bromism [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum blood urea nitrogen and creatinine to identify patients with renal insufficiency who may have delayed elimination of DXM and its metabolites after overdose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver enzyme studies (aspartate transferase [AST], alanine transferase [ALT]) to determine presence of liver injury; if abnormal, prothrombin time (PT) and partial thromboplastin time (PTT) to establish baseline values.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum creatine phosphokinase in patients with agitation, seizures, or likely serotonin syndrome to diagnose rhabdomyolysis. Urine tests that are supportive but not diagnostic for rhabdomyolysis include reddish brown discoloration, rapid urine dipstick that is positive for heme, and the presence of urine myoglobin. (See
         <a class="medical medical_review" href="/z/d/html/5169.html" rel="external">
          "Rhabdomyolysis: Clinical manifestations and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum ethanol concentration, to identify patients at a higher risk for coma with respiratory depression due to co-ingestion of DXM and ethanol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A plasma salicylate concentration, especially in patients with altered mental status, tachypnea, tachycardia, vomiting, or evidence for an anion gap metabolic acidosis. (See
         <a class="medical medical_review" href="/z/d/html/329.html" rel="external">
          "Salicylate (aspirin) poisoning: Clinical manifestations and evaluation", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid urine toxicology screen for drugs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid urine pregnancy test in postmenarchal women.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrocardiogram (EKG), to evaluate for drug-induced cardiac electrical dysfunction (especially sodium channel blockade [eg, prolonged QRS complex and/or significant R wave in lead aVR] or QTc prolongation) [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest radiography, if the history or exam suggests the possibility of pulmonary aspiration.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16199387">
         <span class="h2">
          Role of dextromethorphan testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         DXM poisoning is usually diagnosed based on history and clinical findings. Commonly available rapid urine drug screens rely on immunoassay techniques that do not detect DXM [
         <a href="#rid18">
          18
         </a>
         ]. However, DXM will frequently cause a false positive for phencyclidine (PCP) on rapid tests that utilize liquid chromatography [
         <a href="#rid50">
          50-52
         </a>
         ].
        </p>
        <p>
         Quantitative and qualitative testing for DXM is available from dedicated toxicology reference laboratories with methodology such as gas chromatography or mass spectroscopy. However, the results usually cannot be obtained in time to be useful for patient management. Thus, specific measurement of DXM in the blood or other fluids is typically performed only for forensic or other nonclinical purposes.
        </p>
        <p class="headingAnchor" id="H24717885">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          Dextromethorphan
         </a>
         (DXM) poisoning is a clinical diagnosis. The emergency provider should suspect DXM ingestion in youth, young adults, and adults who have abrupt change in behavior associated with hallucinations, gait disturbance, and clinical findings of sympathetic stimulation (dilated pupils, tachycardia, and diaphoresis). Infants and young children may have an acute onset of altered mental status ranging from coma to irritability.
        </p>
        <p>
         The clinical diagnosis of DXM poisoning may also be supported by a false positive for phencyclidine (PCP) on rapid tests that utilize liquid chromatography as well as a negative anion gap or elevated chloride (in setting of bromism). Quantitative and qualitative testing for DXM is available but not usually performed for diagnostic purposes. (See
         <a class="local">
          'Role of dextromethorphan testing'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are many causes of neurobehavioral changes with psychotic features that deserve consideration when evaluating the patient with suspected
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         (DXM) poisoning  (
         <a class="graphic graphic_table graphicRef52785" href="/z/d/graphic/52785.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef50275" href="/z/d/graphic/50275.html" rel="external">
          table 6
         </a>
         ). In the poisoned patient, it is especially important to consider hypoglycemia and potential traumatic brain injury. The approach to acute onset psychosis in children is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6440.html" rel="external">
          "Emergency department approach to acute-onset psychosis in children"
         </a>
         .)
        </p>
        <p>
         Toxicologic causes of ataxia, nystagmus, and mental status changes include ethanol (a common co-ingestant with DXM),
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , phencyclidine (PCP), methoxetamine,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         . The clinical findings after overdose of these agents may be very similar. The specific agent causing toxicity can be identified by history; serum concentrations of ethanol, lithium, phenytoin, and carbamazepine; and rapid urine testing for PCP. (See
         <a class="medical medical_review" href="/z/d/html/6487.html" rel="external">
          "Ethanol intoxication in children: Clinical features, evaluation, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/333.html" rel="external">
          "Ethanol intoxication in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6506.html" rel="external">
          "Phencyclidine (PCP) intoxication in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/313.html" rel="external">
          "Phencyclidine (PCP) intoxication in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/317.html" rel="external">
          "Intoxication from LSD and other common hallucinogens"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/298.html" rel="external">
          "Ketamine poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/320.html" rel="external">
          "Lithium poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/332.html" rel="external">
          "Carbamazepine poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/312.html" rel="external">
          "Phenytoin poisoning"
         </a>
         .)
        </p>
        <p>
         Wernicke-Korsakoff syndrome, serotonin syndrome from agents other than DXM, and abstinence syndromes (eg, ethanol withdrawal) have findings that overlap significantly with DXM toxicity, but are more commonly seen in adults [
         <a href="#rid6">
          6
         </a>
         ]. A history of alcohol use disorder or ingestion of another serotonergic agent is essential to recognize these conditions. (See
         <a class="medical medical_review" href="/z/d/html/4818.html" rel="external">
          "Wernicke encephalopathy", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes", section on 'Delirium tremens'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)", section on 'Clinical features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H3493194255">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H275830261">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">
          "Society guideline links: General measures for acute poisoning treatment"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112688.html" rel="external">
          "Society guideline links: Poisoning prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacology
         </strong>
         -
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          Dextromethorphan
         </a>
         (d-3-methoxy-N-methylmorphinan, DXM) is an over-the-counter (OTC) cough suppressant that is commonly diverted for illicit recreational use among teenagers and young adults. While structurally related to the opioid receptor agonist
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         , DXM in overdose expresses a unique combination of euphoric, stimulant, and dissociative effects in older children and adolescents that is similar to
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and phencyclidine (PCP). (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Pharmacology and cellular toxicology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxic dose and onset
         </strong>
         – DXM toxicity occurs in a dose dependent fashion. Neurobehavioral effects typically begin 30 to 60 minutes after ingestion and persist for up to six hours. (See
         <a class="local">
          'Toxic dose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Manifestations in children
         </strong>
         – In infants and children, DXM poisoning may follow excessive dosing by a caregiver in attempts to treat an upper respiratory illness. Exploratory ingestions in young children and infants usually have minimal symptoms but have the potential to cause marked respiratory depression and apnea. (See
         <a class="local">
          'Children'
         </a>
         above and
         <a class="local">
          'Physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Manifestations in adolescents and adults
         </strong>
         –
         <strong>
         </strong>
         Prominent clinical findings of DXM overdose in teenagers and adults consist of neurobehavioral changes (eg, euphoria, hallucinations, inappropriate laughing, psychosis with dissociative features, agitation, and coma), tachycardia, dilated pupils, diaphoresis, and "zombie-like" ataxic gait. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of serotonin syndrome (serotonin toxicity)
         </strong>
         – DXM may also precipitate serotonin syndrome (altered mental status, seizures, autonomic instability, and muscular hypertonicity) alone in overdose and in regular daily dosing when inappropriately combined with monoamine oxidase inhibitors, serotonin specific reuptake inhibitors,
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          tramadol
         </a>
         , and other serotonergic agents  (
         <a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         and
         <a class="local">
          'Physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potential for co-ingestants
         </strong>
         – With DXM poisoning, additional toxicity derives from the ingestion of other ingredients in common OTC cough and cold medications such as
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , antihistamines, and decongestants  (
         <a class="graphic graphic_table graphicRef94240" href="/z/d/graphic/94240.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Formulation'
         </a>
         above and
         <a class="local">
          'Co-ingestant findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of DXM poisoning depends upon recognition of the clinical presentation and exclusion of other causes for acute psychosis, especially hypoglycemia and hypoxia  (
         <a class="graphic graphic_table graphicRef52785" href="/z/d/graphic/52785.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef50275" href="/z/d/graphic/50275.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – The treatment of DXM poisoning is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6492.html" rel="external">
          "Dextromethorphan poisoning: Management"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration. Office of Applied Studies. The NSDUH report: misuse of over-the-counter cough and cold medications among persons aged 12 to 25. http://www.oas.samhsa.gov/2k8/cough/cough.cfm (Accessed on December 16, 2008).
         </li>
         <li class="breakAll">
          Ball JK, Albright V. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Emergency department visits involving dextromethorphan. The New DAWN report 2006; 32:1. http://www.oas.samhsa.gov/DAWN/dextromethorphan.cfm (Accessed on December 16, 2008).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abanades S, Peiró AM, Farré M. [Club drugs: old medicines as new party drugs]. Med Clin (Barc) 2004; 123:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung H, Park M, Hahn E, et al. Recent trends of drug abuse and drug-associated deaths in Korea. Ann N Y Acad Sci 2004; 1025:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shulgin AT. Drugs of abuse in the future. Clin Toxicol 1975; 8:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe TR, Caravati EM. Massive dextromethorphan ingestion and abuse. Am J Emerg Med 1995; 13:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerji S, Anderson IB. Abuse of Coricidin HBP cough &amp; cold tablets: episodes recorded by a poison center. Am J Health Syst Pharm 2001; 58:1811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirages TJ, Sulé HP, Mycyk MB. Severe manifestations of coricidin intoxication. Am J Emerg Med 2003; 21:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desai S, Aldea D, Daneels E, et al. Chronic addiction to dextromethorphan cough syrup: a case report. J Am Board Fam Med 2006; 19:320.
          </a>
         </li>
         <li class="breakAll">
          Department of Health and Human Services. Trouble in the medicine chest (I): Rx drug abuse growing. http://ncadi.samhsa.gov/govpubs/prevalert/v6/4.aspx (Accessed on January 29, 2008).
         </li>
         <li class="breakAll">
          Watson, W. Toxic exposure surveillance system dextromethorphan data. American Association of Poison Control Centers, Washington, DC 2003.
         </li>
         <li class="breakAll">
          Drug Abuse Warning Network. Emergency department visits involving dextromethorphan, 2006 http://www.oas.samhsa.gov (Accessed on January 29, 2008).
         </li>
         <li class="breakAll">
          National Survey on Drug Use and Health. Misuse of Over-the-Counter Cough and Cold Medications among Persons Aged 12 to 25, 2008. http://www.oas.samhsa.gov (Accessed on January 29, 2008).
         </li>
         <li class="breakAll">
          Boyer EW. 2003 Poisoning Data: Massachusetts Poison Control Center, 2003.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simone K, Bottei E, Siegel E, et al. Coricidin abuse in Ohio teens and young adults. J Toxicol Clin Toxicol 2000; 38:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hendrickson RG, Cloutier RL. "Crystal dex:" free-base dextromethorphan. J Emerg Med 2007; 32:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hendrickson RG. "DXemon juice:" analytical evaluation of an extraction process for the purification and freebasing of dextromethorphan from cold preparations. J Med Toxicol 2008; 4:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyer EW. Dextromethorphan abuse. Pediatr Emerg Care 2004; 20:858.
          </a>
         </li>
         <li class="breakAll">
          O'Brien M. Emerging trends in drug use. Community Epidemiology Working Group Annual Conference. National Institutes on Drug Abuse. Atlanta 2003.
         </li>
         <li class="breakAll">
          Boyer E. Dissociative agents: Phencyclidine, ketamine, and dextromethorphan. In: Haddad adn Winchester's Clinical Management of Poisoning and Drug Overdose, 4th, Shannon MW, Borron SW, Burns MJ (Eds), Saunders, Philadelphia 2007. p.776.
         </li>
         <li class="breakAll">
          White, W. DXM FAQ, 1995. http://www.erowid.org (Accessed on January 29, 2008).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Logan BK, Yeakel JK, Goldfogel G, et al. Dextromethorphan abuse leading to assault, suicide, or homicide. J Forensic Sci 2012; 57:1388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siu A, Drachtman R. Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain. CNS Drug Rev 2007; 13:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HS, Park IS, Lim HK, Choi HS. NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in PCPA-treated mice. Arch Pharm Res 1999; 22:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganetsky M, Babu KM, Boyer EW. Serotonin syndrome in dextromethorphan ingestion responsive to propofol therapy. Pediatr Emerg Care 2007; 23:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamei J, Mori T, Igarashi H, Kasuya Y. Serotonin release in nucleus of the solitary tract and its modulation by antitussive drugs. Res Commun Chem Pathol Pharmacol 1992; 76:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinmiller CL, Maisonneuve IM, Glick SD. Effects of dextromethorphan on dopamine release in the nucleus accumbens: Interactions with morphine. Pharmacol Biochem Behav 2003; 74:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graudins A, Fern RP. Acute dystonia in a child associated with therapeutic ingestion of a dextromethorphan containing cough and cold syrup. J Toxicol Clin Toxicol 1996; 34:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warden CR, Diekema DS, Robertson WO. Dystonic reaction associated with dextromethorphan ingestion in a toddler. Pediatr Emerg Care 1997; 13:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnhart JW, Massad EN. Determination of dextromethorphan in serum by gas chromatography. J Chromatogr 1979; 163:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silvasti M, Karttunen P, Tukiainen H, et al. Pharmacokinetics of dextromethorphan and dextrorphan: a single dose comparison of three preparations in human volunteers. Int J Clin Pharmacol Ther Toxicol 1987; 25:493.
          </a>
         </li>
         <li class="breakAll">
          Baselt R, Cravey R. Disposition of Toxic Drugs and Chemicals in Man, Yearbook, Chicago 1989.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schadel M, Wu D, Otton SV, et al. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 1995; 15:263.
          </a>
         </li>
         <li class="breakAll">
          Pharmacokinetic data. In: Goodman &amp; Gilman's The Pharmacologic Basis of Therapeutics, 11th, Brunton LL, Lazo JS, Parker KL (Eds), McGraw HIll, New York 2006. p.1816.
         </li>
         <li>
          <a class="nounderline abstract_t">
           LoVecchio F, Pizon A, Matesick L, O'Patry S. Accidental dextromethorphan ingestions in children less than 5 years old. J Med Toxicol 2008; 4:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paul IM, Reynolds KM, Kauffman RE, et al. Adverse events associated with pediatric exposures to dextromethorphan. Clin Toxicol (Phila) 2017; 55:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowdle TA. Adverse effects of opioid agonists and agonist-antagonists in anaesthesia. Drug Saf 1998; 19:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaul WL, Wandell M, Robertson WO. Dextromethorphan toxicity: reversal by naloxone. Pediatrics 1977; 59:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henretig FM. Special considerations in the poisoned pediatric patient. Emerg Med Clin North Am 1994; 12:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helfer J, Kim OM. Psychoactive abuse potential of Robitussin-DM. Am J Psychiatry 1990; 147:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinsberger A, Sharma V, Mazmanian D. Cognitive deterioration from long-term abuse of dextromethorphan: a case report. J Psychiatry Neurosci 1994; 19:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming PM. Dependence on dextromethorphan hydrobromide. Br Med J (Clin Res Ed) 1986; 293:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dodds, A. Toxic psychosis due to dextromethorphan. Med J Aust 1967; 2:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schadel M, Sellers EM. Psychosis with Vicks Formula 44-D abuse. CMAJ 1992; 147:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein LB, Albert D, Baguer C, Popiel M. Long-term Dextromethorphan Use and Acute Intoxication Results in an Episode of Mania and Autoenucleation. J Addict Med 2020; 14:e133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson KL, Hayes BA, Balster RL. Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology (Berl) 1999; 146:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng YY, Lin WL, Chen TW, et al. Spurious hyperchloremia and decreased anion gap in a patient with dextromethorphan bromide. Am J Nephrol 1992; 12:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz BZ. Bromism from excessive cola consumption. J Toxicol Clin Toxicol 1997; 35:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med 1995; 26:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darboe MN, Keenan GR Jr, Richards TK. The abuse of dextromethorphan-based cough syrup: a pilot study of the community of Waynesboro, Pennsylvania. Adolescence 1996; 31:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schier J. Avoid unfavorable consequences: dextromethorpan can bring about a false-positive phencyclidine urine drug screen. J Emerg Med 2000; 18:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams JF, Kokotailo PK. Abuse of proprietary (over-the-counter) drugs. Adolesc Med Clin 2006; 17:733.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6488 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.oas.samhsa.gov/2k8/cough/cough.cfm" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Substance Abuse and Mental Health Services Administration. Office of Applied Studies. The NSDUH report: misuse of over-the-counter cough and cold medications among persons aged 12 to 25. http://www.oas.samhsa.gov/2k8/cough/cough.cfm (Accessed on December 16, 2008).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.oas.samhsa.gov/DAWN/dextromethorphan.cfm" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Ball JK, Albright V. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Emergency department visits involving dextromethorphan. The New DAWN report 2006; 32:1. http://www.oas.samhsa.gov/DAWN/dextromethorphan.cfm (Accessed on December 16, 2008).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15373979" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : [Club drugs: old medicines as new party drugs].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15542749" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Recent trends of drug abuse and drug-associated deaths in Korea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1220895" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Drugs of abuse in the future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7893303" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Massive dextromethorphan ingestion and abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11596695" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Abuse of Coricidin HBP cough&amp;cold tablets: episodes recorded by a poison center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14574654" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Severe manifestations of coricidin intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672686" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Chronic addiction to dextromethorphan cough syrup: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672686" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Chronic addiction to dextromethorphan cough syrup: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672686" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Chronic addiction to dextromethorphan cough syrup: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672686" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Chronic addiction to dextromethorphan cough syrup: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672686" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Chronic addiction to dextromethorphan cough syrup: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672686" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Chronic addiction to dextromethorphan cough syrup: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Coricidin abuse in Ohio teens and young adults
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17499693" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : "Crystal dex:" free-base dextromethorphan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19031385" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : "DXemon juice:" analytical evaluation of an extraction process for the purification and freebasing of dextromethorphan from cold preparations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15572980" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Dextromethorphan abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15572980" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Dextromethorphan abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15572980" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Dextromethorphan abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15572980" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Dextromethorphan abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22537430" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Dextromethorphan abuse leading to assault, suicide, or homicide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17461892" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10230499" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in PCPA-treated mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18007217" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Serotonin syndrome in dextromethorphan ingestion responsive to propofol therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1636059" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Serotonin release in nucleus of the solitary tract and its modulation by antitussive drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12667894" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effects of dextromethorphan on dopamine release in the nucleus accumbens: Interactions with morphine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8667476" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Acute dystonia in a child associated with therapeutic ingestion of a dextromethorphan containing cough and cold syrup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9220509" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Dystonic reaction associated with dextromethorphan ingestion in a toddler.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/544605" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Determination of dextromethorphan in serum by gas chromatography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3679620" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Pharmacokinetics of dextromethorphan and dextrorphan: a single dose comparison of three preparations in human volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3679620" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Pharmacokinetics of dextromethorphan and dextrorphan: a single dose comparison of three preparations in human volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7593709" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7593709" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19031376" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Accidental dextromethorphan ingestions in children less than 5 years old.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27736263" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Adverse events associated with pediatric exposures to dextromethorphan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9747665" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Adverse effects of opioid agonists and agonist-antagonists in anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/840529" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Dextromethorphan toxicity: reversal by naloxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8187696" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Special considerations in the poisoned pediatric patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2327500" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Psychoactive abuse potential of Robitussin-DM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7803371" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cognitive deterioration from long-term abuse of dextromethorphan: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3092943" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Dependence on dextromethorphan hydrobromide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Toxic psychosis due to dextromethorphan
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1525722" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Psychosis with Vicks Formula 44-D abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31567601" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Long-term Dextromethorphan Use and Acute Intoxication Results in an Episode of Mania and Autoenucleation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10485964" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1481876" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Spurious hyperchloremia and decreased anion gap in a patient with dextromethorphan bromide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9140329" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Bromism from excessive cola consumption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7618783" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8874609" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The abuse of dextromethorphan-based cough syrup: a pilot study of the community of Waynesboro, Pennsylvania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10787303" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Avoid unfavorable consequences: dextromethorpan can bring about a false-positive phencyclidine urine drug screen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17030289" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Abuse of proprietary (over-the-counter) drugs.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
